Adolescents with chronic hepatitis C might be good candidates for direct-acting antiviral therapy.
Ken SatoYuichi YamazakiYuki KanayamaDaisuke UeharaHiroki TojimaTakayoshi SugaSatoru KakizakiNaondo SoharaNorio HoriguchiMasashi NamikawaPublished in: Clinical case reports (2022)
Three Japanese adolescents with chronic hepatitis C were treated by direct-acting antivirals (DAAs). No adverse events or laboratory abnormalities were observed during and after DAA therapy, and a sustained virological response was achieved in all cases. The emotional functioning of the patients and their mothers were improved after DAA therapy.